Santé Ventures

Remedy Applications Inc., known as Remedy, is a healthcare technology company based in Austin, Texas, founded in 2015. The company specializes in on-demand urgent and primary care services, offering innovative delivery methods for healthcare. Remedy provides 24/7 telemedicine, nurse access, lab visits, and house calls, allowing individual patients and large employer clients to receive quality medical care at home. Its software facilitates the booking of healthcare professionals, including nurses and doctors, who are registered with the company, to conduct regular checkups and provide necessary treatment. Through its services, Remedy aims to make healthcare more accessible and affordable for patients.

HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.

Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.

HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.

TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.

Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.

Lumos Pharma is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to developing and commercializing therapeutics for severe, rare, and genetic diseases. Its lead candidate, LUM-201, is an oral growth hormone stimulating small molecule currently undergoing Phase 2 clinical trials for pediatric growth hormone deficiency. The company also holds a licensing agreement with Ellipses Pharma Limited to develop and commercialize nanoparticle formulations for oncology indications. Additionally, Lumos Pharma is focused on treating Creatine Transporter Deficiency, leveraging technology from the University of Cincinnati and collaborating with Key Opinion Leaders and the National Institutes of Health. Founded in 2011, Lumos Pharma aims to address unmet medical needs through innovative therapies.

HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.

TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.

HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.

TVA Medical, Inc. is a medical device company based in Austin, Texas, that specializes in the development and manufacture of catheter-based equipment and solutions aimed at treating end-stage renal disease (ESRD) and peripheral vascular diseases. Founded in 2009, TVA Medical focuses on creating innovative and minimally invasive therapies to improve patient outcomes. The company has garnered funding from Santé Ventures and operates as a subsidiary of Becton, Dickinson and Company since July 2018.

Terapio is developing a pipeline of therapies based on the normally-occurring transport protein RLIP76 that moves free-radical toxins out of cells before significant damage can occur. Although naturally present in cells, increasing the amount of this protein available to normal cells affords them an even greater ability to deal with toxins from a variety of sources, including chemicals and radiation.

HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.

HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.

HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.

HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.

HNI Healthcare, formerly known as Hospitalists Now, is a physician practice management company that utilizes technology to enhance the delivery of facility-based physician programs. The company is dedicated to improving patient care quality by implementing a clinically integrated care model. Through its comprehensive platform, HNI Healthcare enables hospitals and physicians to focus on value-based patient care, allowing healthcare facilities to track and improve key quality and performance metrics. By streamlining processes and leveraging advanced technologies, HNI Healthcare aims to foster better healthcare outcomes and elevate the standards of care within the healthcare system.